AGE Antibody Targeting Senescent Cells in Neurodegenerative Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Neurodegenerative disorders are associated with abnormal cellular senescence, leading to inflammation and tissue damage, and existing immunotherapies for these disorders have limitations in effectively targeting and removing senescent cells within the central nervous system and muscle tissues.
Innovation Solution
Administration of AGE antibodies that bind to AGE-modified proteins on senescent glial cells and myoblasts to induce apoptosis, using mechanisms like ADCC or conjugation with toxins or magnetic nanoparticles to selectively target and remove these cells, supplemented by stem cell transplantation for replacement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immunotherapies are used to target senescent cells, then treatment is provided, but effectiveness in removing senescent cells within the central nervous system and muscle tissues is limited
Solution Approach 1:
The patent uses AGE antibodies as intermediaries that specifically bind to advanced glycation end-products on senescent cells. These antibodies serve as mediators that bridge the therapeutic agent and the target senescent cells, enabling selective recognition and removal of senescent cells while sparing healthy cells. The antibodies can be conjugated to toxins or magnetic nanoparticles to enhance their ability to eliminate senescent cells from the central nervous system and muscle tissues.
2Object-generated harmful factors
If AGE antibodies are administered to kill senescent cells, then senescent cells are removed and inflammation is reduced, but potential side effects from antibody therapy may occur
Solution Approach 1:
The therapy applies local quality by targeting specifically senescent cells through AGE antibody binding, rather than affecting all cells uniformly. The AGE antibodies selectively recognize and bind to advanced glycation end-products that are present on senescent cells but absent or minimal on healthy cells. This selective targeting ensures that only the harmful senescent cells are eliminated while healthy cells remain unaffected, thereby reducing inflammation and tissue damage without causing widespread side effects.
3Reliability
If senescent cells are eliminated to treat neurodegenerative disorders, then age-related phenotypes are delayed, but the complexity of delivering therapy to the central nervous system increases
Solution Approach 1:
The AGE antibodies serve as intermediaries that can be administered systemically and then selectively accumulate at senescent cells within the central nervous system. The antibodies act as mediators that navigate the blood-brain barrier and selectively bind to target cells, simplifying the delivery mechanism compared to direct CNS intervention methods. This approach allows for delayed age-related phenotypes through senescent cell elimination without requiring complex CNS-specific delivery systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Effectively kills senescent cells, reducing inflammation and promoting tissue repair in neurodegenerative disorders and muscle diseases like AD, PD, and ALS, with minimal side effects.
Implementation Method 1
using mechanisms like ADCC or conjugation with toxins or magnetic nanoparticles to selectively target and remove these cells
Data Source
AI summary
A method of treating a neurodegenerative disorder or MD comprises administering to a subject a composition comprising an AGE antibody.